Skip to main content
Premium Trial:

Request an Annual Quote

Twist Bioscience, Vivlion Partner on Guide RNA Libraries for CRISPR Applications

NEW YORK – Twist Bioscience said on Wednesday it is partnering with Vivlion to generate guide RNA, or gRNA, libraries for use in CRISPR studies.

Under the terms of the deal, Vivlion will purchase Twist's oligo pools to generate and sell precision CRISPR libraries for functional genomics research. Vivlion's proprietary 3Cs technology bypasses standard cloning methods such as PCR amplification, allowing direct conversion of Twist's oligo pools into gRNA libraries that maintain uniformity, including the generation of multiplexed and fixed-pair libraries.

"Twist is the ideal partner for the oligos needed for our CRISPR libraries. Their market expertise and ability to quickly generate large quantities of long, high-quality oligonucleotides provides Vivlion with a ready-made platform to amplify our impact," Vivlion CEO Ivan Dikic said in a statement. "The combined technologies have the potential to accelerate genomic research and enable scientists to decipher the function of genes more quickly."

Germany-based Vivlion is a spinout from Goethe University Frankfurt am Main offering gene editing reagents and screening services for the global R&D market.

In December 2020, Vivlion obtained a non-exclusive license to ERS Genomics' CRISPR-Cas9 patent portfolio.

 

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.